Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more
Market Cap & Net Worth: Wanbury Limited (WANBURY)
Wanbury Limited (NSE:WANBURY) has a market capitalization of $99.95 Million (₹8.66 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #21159 globally and #1072 in its home market, demonstrating a 1.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wanbury Limited's stock price ₹247.75 by its total outstanding shares 34939398 (34.94 Million).
Wanbury Limited Market Cap History: 2015 to 2026
Wanbury Limited's market capitalization history from 2015 to 2026. Data shows growth from $37.10 Million to $99.95 Million (13.61% CAGR).
Wanbury Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wanbury Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Wanbury Limited's market cap is 0.02 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.30x
Wanbury Limited's market cap is 0.30 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $24.85 Million | $4.23 Billion | -$71.46 Million | 0.01x | N/A |
| 2017 | $17.91 Million | $4.29 Billion | $620.15 Million | 0.00x | 0.03x |
| 2018 | $8.21 Million | $3.68 Billion | -$320.08 Million | 0.00x | N/A |
| 2019 | $7.50 Million | $3.87 Billion | -$248.48 Million | 0.00x | N/A |
| 2020 | $18.82 Million | $3.63 Billion | $644.62 Million | 0.01x | 0.03x |
| 2021 | $34.03 Million | $3.87 Billion | -$126.06 Million | 0.01x | N/A |
| 2022 | $19.77 Million | $5.11 Billion | $814.74 Million | 0.00x | 0.02x |
| 2023 | $50.85 Million | $4.98 Billion | -$103.96 Million | 0.01x | N/A |
| 2024 | $117.47 Million | $5.74 Billion | $559.56 Million | 0.02x | 0.21x |
| 2025 | $91.42 Million | $6.00 Billion | $305.30 Million | 0.02x | 0.30x |
Competitor Companies of WANBURY by Market Capitalization
Companies near Wanbury Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Wanbury Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Wanbury Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Wanbury Limited's market cap moved from $37.10 Million to $ 99.95 Million, with a yearly change of 13.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹99.95 Million | +9.33% |
| 2025 | ₹91.42 Million | -22.18% |
| 2024 | ₹117.47 Million | +131.00% |
| 2023 | ₹50.85 Million | +157.24% |
| 2022 | ₹19.77 Million | -41.91% |
| 2021 | ₹34.03 Million | +80.81% |
| 2020 | ₹18.82 Million | +150.81% |
| 2019 | ₹7.50 Million | -8.60% |
| 2018 | ₹8.21 Million | -54.17% |
| 2017 | ₹17.91 Million | -27.92% |
| 2016 | ₹24.85 Million | -33.01% |
| 2015 | ₹37.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Wanbury Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $99.95 Million USD |
| MoneyControl | $99.95 Million USD |
| MarketWatch | $99.95 Million USD |
| marketcap.company | $99.95 Million USD |
| Reuters | $99.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.